Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1247-1254

  Nakayama, Shintaro ^a   Takakusa, Hideo ^a   Watanabe, Akiko ^a   Miyaji, Yoshihiro ^a   Suzuki, Wataru ^a   Sugiyama, Daisuke ^a   Shiosakai, Kazuhito ^a   Honda, Kokichi ^a   Okudaira, Noriko ^a   Izumi, Takashi ^a   Okazaki, Osamu ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ATORVASTATIN; BENZBROMARONE; CARBAMAZEPINE; CELECOXIB; CLOPIDOGREL; CLOZAPINE; DONEPEZIL; DRUG METABOLITE; FLUTAMIDE; FUROSEMIDE; IMIPRAMINE; LEVOFLOXACIN; NEVIRAPINE; OLANZAPINE; OLMESARTAN; PIOGLITAZONE; PRAVASTATIN; PROPRANOLOL; ROSIGLITAZONE; SULFAMETHOXAZOLE; TACRINE; TAMOXIFEN; TICLOPIDINE; TIENILIC ACID; UNINDEXED DRUG; VALSARTAN; WARFARIN; ZAFIRLUKAST; ZOMEPIRAC;

ACCURACY; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG DETERMINATION; ENZYME INACTIVATION; GSH TRAPPING ASSAY; LIVER MICROSOME; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TIME DEPENDENT INHIBITION ASSAY;

GLUTATHIONE; PHARMACOLOGY; SULFUR RADIOISOTOPES;

EID: 79959400794     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.039180     Document Type: Article

References (56)

1. Alvarez-Sanchez R, Montavon F, Hartung T, and Pähler A (2006) Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chem Res Toxicol 19:1106-1116. (Pubitemid 44384842)
2. Baillie TA (1992) Metabolism of valproate to hepatotoxic intermediates. Pharm Weekbl Sci 14:122-125.
3. Baillie TA (2006) Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxicol 19:889-893.
4. Bauman JN, Kelly JM, Tripathy S, Zhao SX, Lam WW, Kalgutkar AS, and Obach RS (2009) Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from non-hepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem Res Toxicol 22:332-340.
5. Chang SY, Chen C, Yang Z, and Rodrigues AD (2009) Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro. Drug Metab Dispos 37:1667-1675.
6. Coles B, Wilson I, Wardman P, Hinson JA, Nelson SD, and Ketterer B (1988) The spontaneous and enzymatic reaction of N-acetyl-p-benzoquinonimine with glutathione: a stopped-flow kinetic study. Arch Biochem Biophys 264:253-260.
7. Cribb AE, Miller M, Leeder JS, Hill J, and Spielberg SP (1991) Reactions of the nitroso and hydroxylamine metabolites of sulfamethoxazole with reduced glutathione. Implications for idiosyncratic toxicity. Drug Metab Dispos 19:900-906.
8. Dansette PM, Libraire J, Bertho G, and Mansuy D (2009) Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. Chem Res Toxicol 22:369-373.
9. Evans DC, Watt AP, Nicoll-Griffith DA, and Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-16. (Pubitemid 38134055)
10. Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metab Dispos 37:1355-1370.
11. Hollenberg PF, Kent UM, and Bumpus NN (2008) Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 21:189-205. (Pubitemid 351219719)
12. 14C]cyanide. Drug Metab Pharmacokinet 24:245-254.
13. Jean P, Lopez-Garcia P, Dansette P, Mansuy D, and Goldstein JL (1996) Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Eur J Biochem 241:797-804. (Pubitemid 26379382)
14. Ju C and Uetrecht JP (1998) Oxidation of a metabolite of indomethacin (Desmethyldeschlorobenzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system. Drug Metab Dispos 26:676-680. (Pubitemid 28345851)
15. Kalgutkar AS, Obach RS, and Maurer TS (2007) Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8:407-447. (Pubitemid 47603408)
16. Kang P, Dalvie D, Smith E, Zhou S, and Deese A (2007) Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos 35:1081-1088. (Pubitemid 46956427)
17. Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489-499.
18. Kassahun K, Skordos K, McIntosh I, Slaughter D, Doss GA, Baillie TA, and Yost GS (2005) Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic alpha,beta-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme. Chem Res Toxicol 18:1427-1437. (Pubitemid 41361716)
19. Kent UM, Lin HL, Mills DE, Regal KA, and Hollenberg PF (2006) Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chem Res Toxicol 19:279-287.
20. Kumar S, Wong H, Yeung SA, Riggs KW, Abbott FS, and Rurak DW (2000) Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination. Drug Metab Dispos 28:857-864. (Pubitemid 30470836)
21. Kumar S, Kassahun K, Tschirret-Guth RA, Mitra K, and Baillie TA (2008) Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions. Curr Opin Drug Discov Dev 11:43-52.
22. Kumar S, Mitra K, Kassahun K, and Baillie TA (2009) Approaches for minimizing metabolic activation of new drug candidates in drug discovery. Handb Exp Pharmacol 511-544.
23. Larrey D, Tinel M, and Pessayre D (1983) Formation of inactive cytochrome P-450 Fe(II)- metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem Pharmacol 32:1487-1493. (Pubitemid 13096006)
24. Lim HK, Duczak N Jr, Brougham L, Elliot M, Patel K, and Chan K (2005) Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos 33:1211-1219. (Pubitemid 41043765)
25. Liu ZC and Uetrecht JP (2000) Metabolism of ticlopidine by activated neutrophils: implications for ticlopidine-induced agranulocytosis. Drug Metab Dispos 28:726-730. (Pubitemid 30470819)
26. Luo G, Lin J, Fiske WD, Dai R, Yang TJ, Kim S, Sinz M, LeCluyse E, Solon E, Brennan JM, et al. (2003) Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab Dispos 31:1170-1175. (Pubitemid 37048289)
27. Madden S, Woolf TF, Pool WF, and Park BK (1993) An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol 46:13-20. (Pubitemid 23218576)
28. Masubuchi Y, Nakano T, Ose A, and Horie T (2001) Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver. Arch Toxicol 75:538-543. (Pubitemid 33044112)
29. Masubuchi Y, Ose A, and Horie T (2002) Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab Dispos 30:1143-1148.
30. Masubuchi N, Makino C, and Murayama N (2007) Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem Res Toxicol 20:455-464. (Pubitemid 46548692)
31. McDonald MG and Rettie AE (2007) Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 20:1833-1842.
32. Meneses-Lorente G, Sakatis MZ, Schulz-Utermoehl T, De Nardi C, and Watt AP (2006) A quantitative high-throughput trapping assay as a measurement of potential for bioactivation. Anal Biochem 351:266-272.
33. Naisbitt DJ, Williams DP, O'Neill PM, Maggs JL, Willock DJ, Pirmohamed M, and Park BK (1998) Metabolism-dependent neutrophil cytotoxicity of amodiaquine: a comparison with pyronaridine and related antimalarial drugs. Chem Res Toxicol 11:1586-1595. (Pubitemid 29013636)
34. Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, and Okazaki O (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos 37:1970-1977.
35. Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, Farid NA, and Ikeda T (2009a) Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug Metab Dispos 37:589-593.
36. Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, and Ikeda T (2009b) Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. Xenobiotica 39:836-843.
37. Obach RS, Kalgutkar AS, Soglia JR, and Zhao SX (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 21:1814-1822.
38. Reese M, Sakatis M, Ambroso J, Harrell A, Yang E, Chen L, Taylor M, Baines I, Zhu L, Ayrton A, et al. (2010) An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. Chem Biol Interact doi:10.1016/ j.cbi.2010.10.005.
39. Riley RJ, Grime K, and Weaver R (2007) Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3:51-66.
40. Rowland K, Yeo WW, Ellis SW, Chadwick IG, Haq I, Lennard MS, Jackson PR, Ramsay LE, and Tucker GT (1994) Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol. Br J Clin Pharmacol 38:9-14. (Pubitemid 24222830)
41. Silverman RB (1995) Mechanism-based enzyme inactivators. Methods Enzymol 249:240-283.
42. Stresser DM, Mason AK, Perloff ES, Ho T, Crespi CL, Dandeneau AA, Morgan L, and Dehal SS (2009) Differential time- and NADPH-dependent inhibition of CYP2C19 by enantiomers of fluoxetine. Drug Metab Dispos 37:695-698.
43. Takakusa H, Masumoto H, Makino C, Okazaki O, and Sudo K (2009) Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione. Drug Metab Pharmacokinet 24:100-107.
44. Tang W and Lu AY (2010) Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective. Drug Metab Rev 42:225-249.
45. Tang W, Stearns RA, Bandiera SM, Zhang Y, Raab C, Braun MP, Dean DC, Pang J, Leung KH, Doss GA, et al. (1999) Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab Dispos 27:365-372. (Pubitemid 29114244)
46. Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, Claesson A, Page K, Dolgos H, and Kenna JG (2010) Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact doi:10.1016/j.cbi.2010.11.002.
47. Uetrecht J (2001) Prediction of a new drug's potential to cause idiosyncratic reactions. Curr Opin Drug Discov Dev 4:55-59.
48. Uetrecht J (2007) Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 47:513-539.
49. Uetrecht JP (1985) Reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J Pharmacol Exp Ther 232:420-425.
50. Usui T, Mise M, Hashizume T, Yabuki M, and Komuro S (2009) Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos 37:2383-2392.
51. Wang M, Gorrell MD, McGaughan GW, and Dickinson RG (2001) Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. Life Sci 68:785-797. (Pubitemid 32168009)
52. Watanabe A, Nakamura K, Okudaira N, Okazaki O, and Sudo K (2007) Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab Dispos 35:1232-1238. (Pubitemid 46956447)
53. Wen B, Chen Y, and Fitch WL (2009) Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab Dispos 37:1557-1562.
54. Williams DP, Pirmohamed M, Naisbitt DJ, Maggs JL, and Park BK (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 283:1375-1382. (Pubitemid 28016513)
55. Yao D, Zhang F, Yu L, Yang Y, van Breemen RB, and Bolton JL (2001) Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones. Chem Res Toxicol 14:1643-1653. (Pubitemid 34016628)
56. Zhang H and Yang Y (2008) An algorithm for thorough background subtraction from high-resolution LC/MS data: application for detection of glutathione-trapped reactive metabolites. J Mass Spectrom 43:1181-1190.